• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Epidemiology, Pathophysiology, and Symptomatology of Friedreich Ataxia

Opinion
Video

A Friedreich ataxia specialist discusses how the typical clinical presentation of Friedreich's Ataxia includes early onset with symptoms such as ataxia and sensory loss, while also examining the pathophysiology and incidence rate of the condition.

Video content above is prompted by the following:

  • Describe the typical clinical presentation of FA in terms of age of onset, initial symptoms, and life expectancy?
  • Can you summarize the pathophysiology and incidence rate of Friedreich's Ataxia (FA)? 
Related Videos
1 expert is featured in this series.
1 expert is featured in this series.
Related Content
Past studies have explored the association between motor and cardiac function in younger patients with DMD, but there is a lack of research on this relationship as patients with DMD age. | Image credit: Nana_studio - stock.adobe.com

Later Loss of Ambulation Linked With Better Heart Health in DMD

January 13th 2025
Article

The results suggest that prolonging ambulation may not adversely impact cardiac function in adulthood for patients with Duchenne muscular dystrophy (DMD).

Read More

Patients with MS had higher odds of filling prescriptions for anticonvulsants and higher odds of filling gabapentinoids and gabapentinoids without other anticonvulsants in the years leading up to onset of MS. | Image credit: Vitalii Vodolazskyi - stock.adobe.com

Pain May Be Indicator of MS Prior to Disease Onset: Study

January 6th 2025
Article

Compared with healthy controls, patients with multiple sclerosis (MS) had higher odds of filling prescriptions for gabapentinoids and other anticonvulsants in the 5 years prior to MS onset.

Read More

Better understanding the vascular sequelae of MS may similarly unlock predictive insights for people with MS, according to investigators. | Image credit: Elena - stock.adobe.com

Meta-Analysis: Vascular Function Worse in People With MS

January 3rd 2025
Article

The differences did not appear to be associated with potential moderating factors like age, sex, or smoking status.

Read More

lab test tubes | Image credit: kwanchaift – stock.adobe.com

Study Highlights Trends, Emerging Innovations in DMD Research

December 22nd 2024
Article

An analysis revealed global trends and emerging focus areas in Duchenne muscular dystrophy (DMD) research, emphasizing the growing impact of precision medicine and gene therapies.

Read More

Nurse helping patient use walker | Image credit: LIGHTFIELD STUDIOS – stock.adobe.com

Genotypes May Influence When Patients With DMD Have Loss of Ambulation

October 9th 2024
Article

A study of 555 patients further solidified genotype-phenotype correlations in Duchenne muscular dystrophy (DMD).

Read More

Currently, 4 exon-skipping drugs are FDA approved for DMD: eteplirsen (Exondys 51), golodirsen (Vyondys 53), casimersen (Amondys 45), and viltolarsen (Viltepso) | Image credit: CrazyJuke - stock.adobe.com

WVE-N531 Shows Promising Efficacy in DMD at Interim FORWARD-53 Analysis

September 26th 2024
Article

In the phase 2 FORWARD-53 study, the exon-skipping oligonucleotide WVE-N531 showed promising safety and efficacy in boys with Duchenne muscular dystrophy (DMD) who are amenable to exon 53 skipping.

Read More

© 2025 MJH Life Sciences
AJMC®
All rights reserved.